Welcome to our dedicated page for Lipella Pharmaceuticals SEC filings (Ticker: LIPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a biotech 10-K packed with clinical data and patent jargon is tough—especially when Lipella Pharmaceuticals’ pipeline spans liposomal platforms, Oral Lichen Planus trials, and hemorrhagic cystitis breakthroughs. If you have ever searched “Lipella Pharmaceuticals SEC filings explained simply” or wondered which Form 4s flagged fresh insider buys, you know the challenge.
Stock Titan’s AI-powered analysis turns that complexity into clarity. You’ll get real-time alerts the moment a “Lipella Pharmaceuticals insider trading Form 4 transactions” post to EDGAR, concise summaries of every quarterly earnings report 10-Q filing, and plain-English highlights from 8-K material events. Our platform pinpoints where R&D expense shifts, clinical-trial results, or new patents appear—so you don’t have to scan hundreds of pages.
Whether you’re tracking dilution risk through the proxy statement executive compensation tables, comparing LP-310 trial spend quarter over quarter, or confirming a “Lipella Pharmaceuticals annual report 10-K simplified” revenue breakout, all filings live here with AI context. Monitor “Lipella Pharmaceuticals Form 4 insider transactions real-time,” study segment notes, or export data for models—every document from 10-K and 10-Q to S-8 is updated instantly and explained in language you can act on.
Lipella Pharmaceuticals (LIPO) filed its Q3 2025 10-Q, reporting continued operating losses and liquidity pressure. The company posted a Q3 net loss of
Nine‑month results show a net loss of
Lipella’s common stock was suspended from Nasdaq on June 20, 2025 and is quoted on OTC; a Form 25‑NSE to delist was filed October 6, 2025. Shares outstanding were 4,620,837 as of November 13, 2025. Program updates note LP‑310 Phase 2a completed with results announced September 18, 2025, while R&D spend shifted from stock‑based comp to outsourced services and salaries.
Lipella Pharmaceuticals Inc. announced a planned board change. On October 20, 2025, Dr. Naoki Yoshimura notified the company of his intention to retire from the Board of Directors, effective December 31, 2025.
The company stated that Dr. Yoshimura’s decision to retire did not result from any disagreement with the company on matters related to operations, policies, or practices.
Lipella Pharmaceuticals, Inc. submitted a Form 25 notification indicating that a class of its securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC.
Nasdaq certifies it has reasonable grounds to file the Form 25 and indicates compliance with the applicable Exchange rules and with 17 CFR 240.12d2-2 provisions for withdrawal or removal. The filing supplies issuer contact details in Pittsburgh but does not disclose timing, reason, or financial effects of the removal.
Lipella Pharmaceuticals (LIPO) filed an 8-K announcing its delisting from the Nasdaq Capital Market. The company released a stockholder letter from CEO Jonathan Kaufman addressing the delisting and outlining plans to relist on a national exchange. The filing includes a press release and stockholder letter as exhibits 99.1 and 99.2.
As an emerging growth company, Lipella provided standard forward-looking statements cautioning that actual outcomes may differ from expectations regarding product candidate development and relisting efforts.
Lipella Pharmaceuticals Inc. ("LIPO") has been formally delisted from the Nasdaq Capital Market. On 20 June 2025 the company received a Nasdaq Hearings Panel letter, dated 17 June 2025, exercising discretionary authority under Listing Rule 5100 to delist the company’s common stock. The Panel cited two rule violations that arose from private placements conducted between December 2024 and March 2025: (i) failure to secure prior shareholder approval for issuances exceeding 20 % of outstanding shares below the minimum price (Rule 5635(d)), and (ii) actions that disparately reduced or restricted existing shareholders’ voting rights (Rule 5640).
Trading in LIPO shares was suspended at the market open on 20 June 2025. The company expects to file Form 25 with the SEC to formally remove its listing. As of the suspension date, the common stock now trades on the OTC Markets Group’s Pink Market under the existing ticker "LIPO".
The 8-K also furnishes a press release (Exhibit 99.1) announcing the delisting. Management emphasises that forward-looking statements in the filing involve significant risk and that the company is evaluating all market alternatives for future listing; however, no concrete remediation plan or timeline is provided.
FAQ
What is the current stock price of Lipella Pharmaceuticals (LIPO)?
What is the market cap of Lipella Pharmaceuticals (LIPO)?
